Keck School of Medicine of USC, Los Angeles, CA, USA; Division of Plastic and Reconstructive Surgery, Keck Medicine of USC, Los Angeles, CA, USA.
Keck School of Medicine of USC, Los Angeles, CA, USA.
Burns. 2024 Jun;50(5):1053-1061. doi: 10.1016/j.burns.2024.02.013. Epub 2024 Feb 28.
The prevalence of neuropathic pain (NP) in burn patients is reported in the literature to be as high as 80%. Given the complexity of NP in burn patients and the wide range of treatments available, a systematic review of the literature is warranted to summarize our current understanding of management and treatment of NP in this population.
This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. The following databases were queried to identify relevant articles: PubMed, Cochrane, Embase, Scopus, Ovid, and Web of Science. The main outcome measures were incidence and management of NP. Secondary outcomes included risk factors for NP.
Included articles presented findings from 11 different countries, capturing outcomes for 4366 patients. Risk factors for neuropathic pain in burn patients were identified, including older age, alcohol and substance abuse, current daily smoking, greater % total body surface area burns (TBSA), and longer hospitalizations. Pharmacologic treatments included gabapentin/pregabalin (n = 7), ascorbic acid (n = 1), and lidocaine (n = 1). Overall, the studies showed varied results regarding the efficacy of pharmacological treatments. While certain studies demonstrated gabapentanoids to be effective in reducing neuropathic symptoms, others found conflicting results. With regards to non-pharmacologic treatments, electroconvulsive therapy (n = 1), electropuncture (n = 1), nerve release/reconstruction (n = 2), and somatosensory feedback rehabilitation (n = 1) were used and demonstrated promise in reducing pain intensity and improving functionality.
Despite NP afflicting the majority of burn patients long after their injury, this systematic review demonstrates insufficient evidence on the pathophysiology, outcomes, and risk factors in NP, as well as the efficacy of various therapies. Future prospective and randomized studies evaluating the etiology of these factors can substantially improve our treatment strategies. This can allow for the development of well-delineated and evidence-based protocols in NP management in hopes of improving quality of life and both psychological and physical function in burn patients.
文献中报道烧伤患者的神经性疼痛(NP)患病率高达 80%。鉴于烧伤患者 NP 的复杂性和可用治疗方法的多样性,有必要对文献进行系统回顾,以总结我们目前对该人群 NP 管理和治疗的理解。
本系统评价按照系统评价和荟萃分析的首选报告项目(PRISMA)指南进行。检索了以下数据库以确定相关文章:PubMed、Cochrane、Embase、Scopus、Ovid 和 Web of Science。主要结局指标是 NP 的发生率和治疗。次要结局指标包括 NP 的危险因素。
纳入的文章来自 11 个不同的国家,共纳入了 4366 名患者的结果。确定了烧伤患者发生神经性疼痛的危险因素,包括年龄较大、酒精和药物滥用、目前每日吸烟、更大的总体表烧伤面积(TBSA)和更长的住院时间。药物治疗包括加巴喷丁/普瑞巴林(n=7)、抗坏血酸(n=1)和利多卡因(n=1)。总体而言,这些研究在药物治疗的疗效方面显示出不同的结果。虽然某些研究表明加巴喷丁类药物可有效减轻神经性症状,但其他研究则得出了相互矛盾的结果。至于非药物治疗,电惊厥疗法(n=1)、电针(n=1)、神经松解/重建(n=2)和体感反馈康复(n=1)已被用于减轻疼痛强度和改善功能,并显示出了一定的前景。
尽管 NP 会在烧伤患者受伤后很长时间影响大多数患者,但本系统评价表明,关于 NP 的病理生理学、结局和危险因素以及各种治疗方法的疗效,证据不足。未来评估这些因素病因的前瞻性和随机研究可以大大改善我们的治疗策略。这可以制定明确和基于证据的 NP 管理方案,希望提高烧伤患者的生活质量以及心理和生理功能。